You won’t believe what the EU just decided for Ukraine – Historic and Controversial!

You won’t believe what the EU just decided for Ukraine – Historic and Controversial!

In a stunning reversal and momentous moment, the European Union decided on Thursday to initiate accession negotiations with war-torn Ukraine, marking a significant shift in Europe’s political landscape. This decision, made during a Brussels summit of the EU’s 27 leaders and chaired by European Council President Charles Michel, signals a clear message of hope to […]

UK fishermen hit jackpot: Record £970m fishing opportunities for 2024

UK fishermen hit jackpot: Record £970m fishing opportunities for 2024

In a groundbreaking move for the UK fishing industry, the UK Government has announced an extraordinary increase in fishing opportunities for 2024, totaling a staggering £970 million. This sensational development, marking a significant uptick from the £900 million value in 2023, ensures that the UK fishing fleet will have access to a whopping 750,000 tonnes […]

ENHERTU receives EU approval for advanced non-small cell lung cancer

ENHERTU receives EU approval for advanced non-small cell lung cancer

The European Union (EU) has given its nod to ENHERTU (trastuzumab deruxtecan) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) that have an activating HER2 (ERBB2) mutation, following platinum-based chemotherapy treatment with or without immunotherapy. This significant decision is backed by the positive outcomes of the DESTINY-Lung02 phase 2 trial, […]

AstraZeneca and Daiichi Sankyo’s Enhertu recommended for EU approval

AstraZeneca and Daiichi Sankyo’s Enhertu recommended for EU approval

AstraZeneca and Daiichi Sankyo’s Enhertu has been recommended for approval in the European Union (EU) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC). Specifically designed for tumors with an activating HER2 (ERBB2) mutation, the drug aims to fill a significant gap in systemic therapy options following platinum-based chemotherapy. Enhertu’s EU […]

G20 Summit unveils India-Middle East-Europe Economic Corridor

G20 Summit unveils India-Middle East-Europe Economic Corridor

In a groundbreaking move that directly challenges China’s Belt and Road Initiative, leaders from India, Saudi Arabia, the European Union, and the United States have officially launched the India-Middle East-Europe Economic Corridor at the G20 Summit in New Delhi. This Economic Corridor aims to connect India with West Asia and Europe. For New Delhi, the […]

Dresden gears up: TSMC, Bosch, Infineon, and NXP announce joint semiconductor investment

Dresden gears up: TSMC, Bosch, Infineon, and NXP announce joint semiconductor investment

In a monumental move strengthening the European semiconductor arena, global tech leaders including TSMC, Robert Bosch, Infineon Technologies, and NXP Semiconductors have unveiled their strategic blueprint to collectively funnel their resources into the European Semiconductor Manufacturing Company (ESMC) GmbH, based in Dresden, Germany. This collaboration, part of the European Chips Act framework, is prepping the […]

Alexion’s Soliris approved for paediatric myasthenia gravis treatment in EU

Alexion’s Soliris approved for paediatric myasthenia gravis treatment in EU

Soliris (eculizumab), the first and only targeted therapy approved for the treatment of paediatric patients with refractory generalised myasthenia gravis (gMG), from Alexion, AstraZeneca Rare Disease has obtained approval for expanded use in the European Union (EU). The approval allows the treatment of gMG in children and adolescents aged six to 17 years who are […]

Gilead’s Trodelvy gains EC approval as new hope for metastatic breast cancer patients

Gilead’s Trodelvy gains EC approval as new hope for metastatic breast cancer patients

In a significant advancement for cancer treatment, the European Commission (EC) has approved Gilead Sciences’ Trodelvy (sacituzumab govitecan) for the treatment of adult patients suffering from unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have undergone endocrine-based therapy, and at least two more systemic therapies in the advanced phase. This medication is now […]

CHMP endorses Merck’s gefapixant for EU approval for chronic cough treatment

CHMP endorses Merck’s gefapixant for EU approval for chronic cough treatment

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approval for gefapixant, an investigational, non-narcotic, oral selective P2X3 receptor antagonist from Merck, also known as MSD outside the United States and Canada. The drug is being developed for adults with refractory or unexplained chronic cough. The European Commission (EC) […]